SearchSearch results for: “”

Stibbe advises Aedifica on the acquisition of a care residence that will be constructed in Leersum. Aedifica acquired the full property of the site from Woudenburcht B.V., a local real estate developer. See for the press release here.

Stibbe represented Simed International in a dispute with the privately-owned Slotervaart hospital in Amsterdam. The Slotervaart hospital claimed that Simed International had sent incorrect invoices to the Slotervaart hospital, which would therefore have b

Stibbe assisted a client in the pharmaceutical sector with conducting an in-depth legal assessment regarding the scope and modalities of the safety features to be added to (the packaging of) medicinal products.

Representing Plantion/FloraHolland in litigation before the District Court.

Representing Grain Millers in an appeal against a fine in the flour sector that resulted in a lower fine.

Representing Universal Corporation in proceedings against the European Commission before the EU General Court with regard to the taking back of the grant of leniency and parent/subsidiary liability.

Advising Forbion Capital Partners on the delisting of Amsterdam Molecular Therapeutics (AMT) Holding.

Advising KLM on several environmental and planning aspects.

Representing Voestalpine (Flamco) in an investigation by the European Commission in the Water Management Products industry resulting in a settlement.

Stibbe advised a plasma protein biotherapeutics company on Belgium's implementation of a new Act on public procurement law that obliges Belgian hospitals to conduct a public procurement process for public contracts for the supply of medicinal products.

Representing Beiersdorf during ACM proceedings into the cosmetics market resulting in a closure of the proceedings.

Stibbe advised a leading biotechnology company on the legal aspects of clinical trials development for biotech medicinal products.

Stibbe assisted a global innovative pharmaceutical company in a complex co-marketing and co-promotion agreement and advised it on the impact of an innovative product’s registration at the European Medicines Agency.